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Purpose: The main objective of this study was to evaluate the association between 
polymorphisms of the target genes of pemetrexed and clinical outcomes in non-
small cell lung cancer (NSCLC) patients treated with pemetrexed. Materials and 
Methods: We assessed polymorphisms at 8 sites in 4 genes [thymidylate synthase 
(TS), dihydrofolate reductase (DHFR; 1610, 680, 317, intron 1), methylenetetra-
hydrofolate reductase (MTHFR; 677, 1298), glycinamide ribonucleotide formyl 
transferase (GARFT; 2255)] associated with pemetrexed metabolism using poly-
merase chain reaction, gene scanning, and restriction fragment length polymor-
phism analysis in 90 patients with adenocarcinoma of the lung. Results: Survival 
was significantly longer with pemetrexed in patients with TS 3RGCC/3RGCC or 
3RGGC/3RGGC compared with the other groups (PFS; 5.2 months vs. 3.7 months, 
p=0.03: OS; 31.8 months vs. 18.5 months, p=0.001). Patients with DHFR 680CC 
experienced fatigue more frequently (50% vs. 8.6%, p=0.008). Polymorphisms of 
MTHFR and GARFT were not significantly associated with clinical outcomes of 
pemetrexed. Conclusion: The TS genotype was associated with survival and one 
DHFR polymorphism was associated with fatigue in NSCLC patients treated with 
pemetrexed. Further large prospective studies are required to identify other bio-
markers that affect patients being treated with pemetrexed for adenocarcinoma of 
the lung.
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INTRODUCTION
Pemetrexed is an important component in the treatment of advanced non-small cell 
lung cancer (NSCLC).1 Pemetrexed acts as a multi-targeted antifolate compound by 
interrupting purine biosynthesis via thymidylate synthase (TS) and dihydrofolate re-
ductase (DHFR) inhibition and pyrimidine biosynthesis via glycinamide ribonucleo-
tide formyl transferase (GARFT) and aminoimidazole carboxamide formyl transfer-
ase inhibition, all of which are key enzymes involved in folic acid metabolism.2  
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plementation with folic acid and vitamin B12.
Patients were evaluated every 6 weeks by computed to-
mography and clinical response was defined according to 
the response evaluation criteria of Response Evaluation 
Criteria In Solid Tumor (RECIST) 1.1 for patients with 
measurable disease.12 Toxicity was scored every 3 weeks ac-
cording to the Common Toxicity Criteria-Adverse Events 
version 4.0. All patients had provided written informed 
consent and the study protocol was approved by the Institu-
tional Review Board of Yonsei University College of Medi-
cine (No 4- 2008-0647). 
Genetic analysis
Genetic analyses were blinded to patient characteristics and 
clinical outcomes. Genomic DNA for analysis of polymor-
phisms was isolated as described previously13 from each 
patient’s peripheral blood. DNA sequencing was performed 
according to the manufacturer’s instructions (Applied Bio-
systems, Foster City, CA, USA) for all genes. Genotyping 
was performed for four DHFR sites (1610, 680, and 317 in 
the promoter, and a 19bp deletion), two sites in MTHFR 
(677 and 1298), one site in GARFT (2255), and the TS 
5’UTR VNTR and C/G polymorphism within the third 
VNTR in the TS promoter. DNA amplification was per-
formed using a PTC-200 thermocycler (MJ Research, 
Waltham, MA, USA). DNA sequencing was performed us-
ing a BigDye Terminator Cycle Sequencing Ready Reac-
tion Kit (Applied Biosystems, Foster City, CA, USA) on an 
ABI Prism 3100 DNA analyzer (Applied Biosystems, Fos-
ter City, CA, USA) for all genes. The primers used for am-
plification and sequencing were as follows: DHFR C1610T 
(sense: 5’-GCCCCCGCCGACAAAAGGGACCCTT 
TCTCCA-3’; antisense: 5’-GTTCACCCATAGGGTTTC 
C-3’), DHFR C680A (sense: 5’-CCCCCGCCGTTCATTG 
CAATTTAAGTGTTTCC-3’; antisense: 5’-ATACTGCCA 
CAGGAAAAGCC-3’), DHFR A317G (sense: ’-GCAGC 
TTTCTTCTAGTCACCC-3’; antisense: 5’-GTAGGTTCT 
GTCTGGGACTGG-3’), DHFR intron 19bp (sense: 5’-AT 
GGGACCCAAACGGGCGCA-3’: antisense: 5’-AAAAG 
GGGAATCCAGTCGG-3’), MTHFR C677T (sense: 
5’-AAGGAGGAGCTGCTGAAGATG-3’; antisense: 5’-
CT TTGCCATGTCCACAGCATG-3’), MTHFR A1298C 
(sense: 5’-AGG ACG GTGCGG TGA GAGTG-3’; anti-
sense: 5’-CAC TTT GTG ACCATT CCG GTT TG-3’), and 
GARFTA2255G (sense: 5’-TTTTTCAGATGCCCAG 
ACCT-3’; antisense: 5’-GAGTAAGGAGCAAGTACCTTC 
AGC-3’). TS 5’UTR VNTR and C/G polymorphism within 
Because TS activity is high in rapidly proliferating cells,3 
it is considered an ideal target for cancer chemotherapeu-
tics. The variable number of tandem repeats (VNTR) and 
single nucleotide polymorphisms (SNPs) in the 5’-untrans-
lated region (UTR) in the TS promoter have repeatedly 
been shown to be correlated with treatment outcomes in pa-
tients with gastrointestinal malignancies who receive fluo-
rouracil.4 Furthermore, functional gene polymorphisms of 
DHFR, methylenetetrahydrofolate reductase (MTHFR), 
and GARFT have been shown to be correlated with out-
comes in patients with rheumatoid arthritis who are treated 
with methotrexate.5,6 
In NSCLC, TS and DHFR expressions have been associ-
ated with sensitivity to pemetrexed.7,8 Moreover, Smit, et 
al.9 reported that, among NSCLC patients who were treated 
with pemetrexed, those with MTHFR C677T had longer 
survival compared with patients with other genotypes. How-
ever, the prevalence of polymorphisms of key proteins in 
folate metabolism has been shown to differ among various 
ethnic populations,10 and more research is needed in Asian 
patients. 
We hypothesized that certain SNPs of TS, DHFR, and 
GARFT, the key enzyme targets of pemetrexed, might be 
predictive markers for the efficacy and toxicity of this agent. 
Thus, we examined the association between TS, DHFR, and 
GARFT SNPs and the clinical outcomes of NSCLC patients 
treated with pemetrexed.
MATERIALS AND METHODS
　　　
Eligible patients and treatment
Ninety patients with advanced NSCLC were enrolled in 
this study. Eligible patients were those diagnosed with cyto-
logically- or histologically-proven lung adenocarcinoma, 
who had an Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) of 0-2, and who had previous treat-
ment with more than one prior chemotherapy regimens for 
advanced NSCLC at Yonsei Cancer Center, Yonsei Univer-
sity College of Medicine, Seoul, Korea, from January 2007 
to December 2010. Baseline characteristics were age, gen-
der, clinical stage, ECOG PS, histological type, smoking 
history, and number of prior chemotherapy regimens. His-
tological analysis of tumors was based on the WHO classi-
fication of cell types.11 Patients received 500 mg/m2 of 
pemetrexed every 3 weeks until disease progression, intol-
erable toxicity, or patient refusal. All patients received sup-
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as a second-line chemotherapy agent. The majority of pa-
tients (86.7%) had good PS (ECOG PS 0 or 1).
Association of baseline characteristics and genotypes 
with response to pemetrexed therapy
Response was evaluated in 88 of 90 patients. Two patients 
were lost to follow-up before response evaluation. One pa-
tient achieved complete remission and 13 patients had a 
partial response, giving a response rate of 15.9%, and 41 
patients (46.6%) had the best response, which was stability 
of disease. No association was found between response rate 
(RR) and age, gender, and smoking. However, patients with 
an ECOG PS 0-1 or those who were treated with peme-
trexed as a second-line agent had a higher RR than patients 
with an ECOG PS 2 or those who were treated with peme-
trexed as a third- or fourth-line agent (Table 2). On the oth-
er hand, male patients, patients with a good PS, and those 
who were treated with pemetrexed as a second-line agent 
had a higher disease control rate. Table 3 shows a compari-
son between the genotypes and response to pemetrexed. No 
significant association was found between response and 
any of the genotypes of DHFR, MTHFR, GARFT, or TS 5’ 
UTR (Table 3). 
Association of baseline characteristics and genotypes 
with survival with pemetrexed therapy
In all 90 patients, the median follow-up duration was 13.4 
months (range, 0.5-52.2 months). The median PFS was 4.4 
months (95% CI, 0.4-13.6 months), and the median OS 
was 23.1 months (95% CI, 16.8-29.4 months). Patients with 
good PS had longer PFS and OS than the patients with an 
ECOG PS 2. In addition, patients treated with pemetrexed 
as a second-line agent had a longer PFS than those who 
were treated with pemetrexed as a third- or fourth-line drug. 
However, no significant differences were found between 
any each genotype itself and survival. The TS genotype 
was categorized into two groups: a high-expression geno-
type (2RGC/3RGGC, 3RGCC/3RGGC, 3RGGC/3RGGC) 
and a low-expression genotype (2RCC/2RGC, 2RGC/ 
3RGCC, 3RGCC/3RGCC) as based on a previous report.14 
Patients with a high expression genotype had a longer OS 
than those with a low-expression genotype (31.8 months 
vs. 21.1 months, p=0.04) (Fig. 1). In addition, 3RGCC/ 
3RGCC or 3RGGC/3RGGC was associated with a longer 
PFS and OS as compared with other genotypes (PFS, 5.2 
months vs. 3.7 months, p=0.03; OS, 31.8 months vs. 18.5 
months, p=0.001) (Table 4 and 5, Fig. 2). Good PS and 
the third tandem repeat (sense: 5’-AAAAGGCGCGCG 
GAAGGGGTCCT-3’; antisense: ’-TCCGAGCCGGCCA 
CAGGCAT-3’). 
Statistical methods
The associations between each genotype and other categor-
ical clinical variables were compared using the χ2 test or 
Fisher’s exact test. Progression-free survival (PFS) was de-
fined as the time from the start day of pemetrexed treatment 
until the date of tumor progression or death. Overall surviv-
al (OS) was measured from the start date of pemetrexed ther-
apy to the date of death or final follow-up. In the absence of 
death, OS was defined using the time of the last visit. Surviv-
al data were estimated using a Kaplan-Meier curve and 
compared using the log-rank test. A p-value of less than 
0.05 was considered statistically significant. SPSS software 
version 15.0 was used for statistical analyses (SPSS Inc., 
Chicago, IL, USA).
 
RESULTS
 
Patient characteristics 
The demographic characteristics of the subjects are shown 
in Table 1. The median age of the patients was 59 years 
(range, 34-85), 36.7% were female, and 42.2% had never 
smoked. Forty-nine patients (54.4%) received pemetrexed 
Table 1. Patient Baseline Characteristics
All patients (n=90)
n %
Age
    Median (range) 59 (34-85)
    ≤65 61 67.8
    >65 29 32.2
Gender
    Female 33 36.7
    Male 57 63.3
ECOG PS
    0 20 22.2
    1 58 64.4
    2 12 13.3
Smoking
    Never 38 42.2
    Ever 52 57.8
Treatment with pemetrexed
    Second-line 49 54.4
    Third- or fourth-line 41 45.6
ECOG PS, Eastern Cooperative Oncology Group performance status.
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ated with survival and one DHFR polymorphism was asso-
ciated with fatigue in patients treated with pemetrexed for 
NSCLC. 
Preclinical data have previously shown that the RNA level 
of TS in tumors is usually lower in non-squamous NSCLC, 
as compared with squamous NSCLC, which may be re-
sponsible for the different activity of pemetrexed.15,16 In ad-
dition, TS is the main cellular target of pemetrexed, and the 
variable number of tandem repeat polymorphisms within 
the TS promoter has been shown to be correlated with treat-
ment outcomes in colorectal cancer patients treated with 
5-fluorouracil.4 Nief, et al.14 studied the association of TS 
G>C genotype with TS catalytic activity and found that the 
TS genotype can be classified into low expression (2RCC/ 
2RGC, 2RGC/3RGCC, 3RGCC/3RGCC) and high expres-
sion genotypes (2RGC/3RGGC, 3RGCC/3RGGC, 3RGGC/ 
3RGGC). They also found that both mRNA expression and 
protein activity were higher in cells with the high-expres-
sion genotype. In the current study, when genotypes were 
grouped according to VNTR (2R/2R, 2R/3R, 3R/3R) with-
out considering the G>C polymorphisms, no significant dif-
ferences could be detected in clinical outcomes for peme-
trexed. However, patients with high expression genotypes 
by Nief’s classification had longer OS than those with low 
expression genotypes (21.1 months vs. 31.8 months, p= 
0.04). Nevertheless, there was no difference of PFS accord-
ing to TS genotypes by Nief’s classification. Interestingly, 
treatment with pemetrexed as a second-line agent were in-
dependent predictive markers for PFS by multivariate anal-
ysis; however, neither TS 3RGCC/3RGCC nor 3RGGC/ 
3RGGC were independent predictive markers. In addition, 
good PS was significantly associated with OS by multivariate 
analysis; however, neither TS 3RGCC/3RGCC nor 3RGGC/ 
3RGGC were independent predictive markers for OS.
Association of genotype and toxicity from pemetrexed
The frequency of pemetrexed-related toxicity was less than 
5% for all categories except hematologic toxicity and fa-
tigue. There was no grade 4 hematologic toxicity and grade 
3 neutropenia, anemia, and thrombocytopenia were experi-
enced by one patient each (Table 5). Overall, 11 patients 
(12.1%) experienced grade 1 or 2 fatigue. Patients with 
DHFR C680C experienced fatigue more commonly than 
those with other genotypes (50% vs. 8.6%, p=0.008) (Table 
5). With the exception of fatigue, no association was found 
between hematologic toxicity and other genotypes.
DISCUSSION
We tested the hypothesis that genetic polymorphisms of the 
target enzymes of pemetrexed might be associated with its 
effects in the treatment of advanced lung adenocarcinoma, 
and found that the genotype of TS was significantly associ-
Table 2. Correlation of Baseline Characteristics with Response to Pemetrexed
All patients (n=90) RR (n=88) DCR (n=88)
n % % p value % p value
All patients 15.9    62.5
Age 59 (34-85) 0.301 0.478
    ≤65 61 67.8 20.0 65
    >65 29 32.2   7.1    57.1
Gender 0.117 0.035
    Female 33 36.7 12.1    48.5
    Male 57 63.3 18.2    70.9
ECOG PS 0.004 0.001
    0 20 22.2 30.0 85
    1 58 64.4 14.0    63.2
    2 12 13.3   0.0    18.2
Smoking 0.478 0.379
    Never 38 42.2 10.8    56.8
    Ever 52 57.8 19.6    66.7
Treatment with pemetrexed 0.003 0.001
    Second-line 49 54.4 19.1    78.7
    Third- or fourth-line 41 45.6 12.2   43.9
ECOG PS, Eastern Cooperative Oncology Group performance status; RR, response rate; DCR, disease control rate. 
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Table 3. Correlation of Baseline Characteristics and Genetic Polymorphisms with Response to Pemetrexed
Number %
RR DCR
% p value % p value
All patients 88 100.0 15.9 62.5
DHFR1610 0.714 0.674
    CC 75   83.3 17.8 64.4
    CG   5     5.6 20 60
    CT 10   11.1   0 50
DHFR680 0.973 0.892
    AA 27   30.0 14.8 66.7
    AC 55   61.1 17 60.4
    CC   8     8.9 12.5 62.5
DHFR317 0.645 0.57
    AA 10   11.1 11.1 66.7
    AG 56   62.2 18.2 58.2
    GG 24   26.7 12.5 62.5
DHFR-19bp indel 0.269 0.562
    Del/del 35   38.9   8.8 67.4
    Ins/del 43   47.8 23.3 65.1
    Ins/ins 12   13.3   9.1 45.5
MTHFR677 0.279 0.7
    CC 24   26.7 21.7 69.6
    CT 47   52.2 19.6 60.9
    TT 19   21.1   0 57.9
MTHFR1298 0.813 0.586
    AA 69   76.7 16.4 59.7
    AC 19   21.1 15.8 73.7
    CC   2     2.2   0 50
GARFT2255 0.815 0.501
    AA 66   73.3 17.2 64.1
    AG 23   25.6 13 60.9
    GG   1     1.1   0   0
TS 5' UTR 0.105 0.398
    2R/2R   3     3.3   0 66.7
    2R/3R 18   20.0 11.1 77.8
    3R/3R 69   76.7 16.7 57.6
TS G>C 0.191 0.665
    2RGC/2RGC   3     3.3   0 66.7
    2RGC/3RGCC   7     7.8 28.6 71.4
    2RGC/3RGGC 11   12.2   0 81.8
    3RGCC/3RGCC 15   16.7 20 46.7
    3RGGC/3RGCC 34   37.8 18.8 62.5
    3RGGC/3RGGC 20   22.2 10.5 57.9
TS 0.511 0.29
    Low expression group* 25   27.8 20 56
    High expression group† 65   72.2 14.3 65
0.348 0.196
    3RGCCC/3RGCC or     
      3RGGC/3RGGC
35   39.8 17.1 54.3
    Others 53   60.2 15.1 67.9
DHFR, dihydrofolate reductase; MTHFR, methylenetetrahydrofolate reductase; GARFT, glycinamide ribonucleotide formyl transferase; TS, thymidylate syn-
thase; UTR, untranslational region; RR, response rate; DCR, disease control rate.
*2RCC/2RGC, 2RGC/3RGCC, 3RGCC/3RGCC.
†2RGC/3RGGC, 3RGCC/3RGGC, 3RGGC/3RGGC.
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Table 4. Univariate and Multivariate Analysis of Progression Free Survival
Univariate  analysis Multivariate analysis
Median 
(months)
95% CI p value
Hazard 
ration
95% CI p value
All patients 4.4 3.6-5.3
Age 0.873
    ≤65 4.7 3.7-5.8
    >65 4.4 1.2-7.5
Gender 0.894
    Female 3.2 1.6-6.4
    Male 4.6 3.6-5.5
ECOG PS 0.002 0.006
    0 11.5 4.1-18.9 1
    1 4.4 3.6-5.3 1.96 1.1-3.6 0.03
    2 1.6 1.2-2.0 3.93 1.7-9.1 0.001
Smoking 0.556
    Never 4.8 1.9-7.6
    Ever 4.2 3.5-5.0
Treatment with pemetrexed 0.003 0.008
    2-line 5.2 2.0-8.4 1
    3-4 line 2.1 1.0-3.1 1.86 1.2-3.0
DHFR1610 0.838
    CC 4.6 0.5-3.6
    CG+CT 4.1 1.5-1.2
DHFR680 0.235
    AA 7.4 3.6-18.6
    AC+CC 4.2 3.4-5.0
DHFR317 0.41
    AA+GG 4.1 2.8-5.5
    AG 4.6 3.5-5.7
DHFR-19bp indel 0.475
    Del/del 4.4 2.3-6.5
    Ins/del+ins/ins 4.6 3.7-5.5
MTHFR677 0.564
    CC+TT 4.2 3.0-5.3
    CT 4.9 3.6-6.3
MTHFR1298 0.756
    AA 4.4 3.5-5.3
    AC+CC 4.9 2.7-7.2
GARFT 0.731
    AA 4.4 3.5-5.3
    AG+GG 3.7 0.7-6.7
TS 0.558
    Low expression group* 4.0 3.6-8.4
    High expression group† 4.4 3.7-5.1
0.03 0.345
    3RGCC/3RGCC or 
      3RGGC/3RGGC
5.2 2.1-8.3 1
    Others 3.7 1.5-5.9 1.28 0.8-2.2
ECOG PS, Eastern Cooperative Oncology Group performance status; DHFR, dihydrofolate reductase; MTHFR, methylenetetrahydrofolate reductase; GARFT, 
glycinamide ribonucleotide formyl transferase; TS, thymidylate synthase; CI, confidence interval.
*2RCC/2RGC, 2RGC/3RGCC, 3RGCC/3RGCC.
†2RGC/3RGGC, 3RGCC/3RGGC, 3RGGC/3RGGC.
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Table 5. Univariate and Multivariate Analysis of Overall Survival
Univariate analysis Multivariate analysis
Median 
(months)
95% CI p value
Hazard 
ration
95% CI p value
All patients 23.1 16.8-29.4
Age 0.533
    ≤65 27.6 17.9-37.2
    >65 21.1 13.1-29.2
Gender 0.075 0.277
    Female 50.0   9.0-92.9   1
    Male 21.0 18.4-23.9   1.56 0.7-3.5
ECOG PS <0.001
    0 50.1 26.9-75.0   1 0.001
    1 21.1 19.8-22.4   4.20 1.4-13.1
    2   3.9   1.0-10.9 11.07 3.3-41.7
Smoking 0.235
    Never 27.6   5.0-50.1
    Ever 21.8 18.3-25.3
Treatment with pemetrexed 0.532
    Second-line 27.4 16.2-38.5
    Third- or fourth-line 23.1 15.8-30.4
DHFR1610 0.401
    CC 27.4 19.8-35.0
    CG+CT 21.8   7.2-36.4
DHFR680 0.956
    AA 23.1 14.9-31.3
    AC+CC 27.4 15.6-39.2
DHFR317 0.737
    AA+GG 21.8 14.9-28.7
    AG 27.4 15.3-39.5
DHFR-19bp indel 0.898
    Del/del 27.6 14.2-40.9
    Ins/del+ins/ins 23.1 15.6-30.6
MTHFR677 0.779
    CC+TT 21.4 11.4-31.4
    CT 27.4 20.8-34.0
MTHFR1298 0.486
    AA 23.1 15.1-31.1
    AC+CC 27.6 19.7-35.4
GARFT 0.928
    AA 23.1 15.3-30.9
    AG+GG 21.4 13.4-29.3
TS 0.04
    Low expression group* 21.1   5.9-36.3
    High expression group† 31.8 15.2-48.3
0.001 0.144
    3RGCC/3RGCC or 
      3RGGC/3RGGC
31.8 20.9-42.6   1
    Others 18.5 13.0-24.0   2 0.8-3.5
ECOG PS, Eastern Cooperative Oncology Group performance status; DHFR, dihydrofolate reductase; MTHFR, methylenetetrahydrofolate reductas; GARFT, 
glycinamide ribonucleotide formyl transferase; TS, thymidylate synthase; CI, confidence interval.
*2RCC/2RGC, 2RGC/3RGCC, 3RGCC/3RGCC.
†2RGC/3RGGC, 3RGCC/3RGGC, 3RGGC/3RGGC.
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in pemetrexed-sensitive lung cancer cell lines.18 However, 
Uramoto, et al.19 reported no association between DHFR 
mRNA and protein expression and clinical response in 
NSCLC treated with pemetrexed. In the current study, no 
significant difference was observed in RR and survival ac-
cording to the different polymorphisms of DHFR. Interest-
ingly, the patients with DHFR 680CC experienced fatigue 
more frequently than the others (p=0.008). To our knowl-
edge, our result is the first report of an association between 
DHFR polymorphisms and fatigue in pemetrexed treatment. 
MTHFR is an enzyme that plays an essential role in the 
metabolism of folate and is also the target of pemetrexed. 
Two common polymorphisms associated with lower en-
zyme activity are 677CT and 1298AC, and the variant geno-
type MTHFR was found to be associated with an increased 
risk of various cancers.20-22 In addition, Smit, et al.9 reported 
TS 3RGCC/3RGCC and 3RGGC/3RGGC were signifi-
cantly associated with both PFS and OS (Table 4 and 5, 
Fig. 2). According to Nief’s classification, 3RGCC/3RGCC 
was classified into low expression genotypes and 3RGGC/ 
3RGGC into high expression genotypes. Also, there is no 
report about the association between the efficacy of peme-
trexed and TS genotypes by Nief’s classification, except the 
current study. Therefore, further validation and investiga-
tion of the efficacy of pemetrexed according to the classifi-
cation of TS genotypes are needed. 
DHFR is the primary target of methotrexate (MTX) and 
pemetrexed, and any polymorphism could be related to 
clinical outcomes for MTX. Dulucq, et al.17 reported that 
DHFR promoter polymorphisms were associated with 
worse outcomes in acute lymphocytic leukemia. A recent 
study reported that DHFR gene downregulation was seen 
Fig. 1. Kaplan-Meier curve estimates for patients treated with pemetrexed. Progression-free survival (PFS) and overall survival (OS) were plotted against the 
expression of thymidylate synthase. Low expression group: 2RCC/2RGC, 2RGC/3RGCC, 3RGCC/3RGCC; high expression group: 2RGC/3RGGC, 3RGCC/3RGGC, 
3RGGC/3RGGC. (A) PFS. (B) OS. TS, thymidylate synthase.
Fig. 2. Kaplan-Meier curve estimates for patients treated with pemetrexed. Progression-free survival (PFS) and overall survival (OS) were plotted by geno-
type. Dotted line-2RCC/2RGC, 2RGC/3RGCC, 2RGC/3RGGC, 3RGCC/3RGGC; straight line-3RGCC/3RGCC and 3RGGC/3RGGC. (A) PFS. (B) OS. TS, thymidylate 
synthase.
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